India’s leading molecular oncology facility, Datar Cancer Genetics has come up with breakthrough 'TriNetra™-Glio', a blood test for diagnosis of inaccessible or inoperable brain tumors.
The company announced that the discovery has gained the attention of the US Food and Drug Administration (FDA), which granted the liquid brain tumor detection test the 'Breakthrough Device Designation.'
